Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BAF53 Double Nickase Plasmid (h): sc-403200-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BAF53 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BAF53 Double Nickase Plasmid (h) and BAF53 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting ACTL6A. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BAF53 Antibody (E-3): sc-137062
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BAF53 Double Nickase Plasmid (h) | sc-403200-NIC | 20 µg | $410.00 | |||
BAF53 Double Nickase Plasmid (h2) | sc-403200-NIC-2 | 20 µg | $410.00 |
ACTL6A encodes BAF53A, an actin-related subunit of the ATP-dependent SWI/SNF (BAF) chromatin remodeling complex that modulates nucleosome positioning and chromatin accessibility. Through regulation of enhancer and promoter landscapes, BAF53A contributes to transcriptional control of cell-cycle progression, lineage specification, and maintenance of proliferative states, intersecting with pathways such as MYC- and E2F-associated transcriptional programs. Altered ACTL6A/BAF53A activity has been linked to dysregulated epigenetic control in multiple cancer contexts and to aberrant developmental gene expression, making it a useful node for studying chromatin-driven phenotypes. Functional interrogation of ACTL6A supports mechanistic research into chromatin remodeling dependencies, transcriptional plasticity, and genome-wide regulatory architecture in human cells.
BAF53 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the ACTL6A locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within ACTL6A. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt ACTL6A function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of ACTL6A-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.